AIDS-Related Kaposi Sarcoma Progressing Despite Antiretroviral Therapy
In AIDS-related Kaposi sarcoma (KS), antiretroviral therapy (ART) is the essential first step — but when KS lesions fail to stabilise or regress despite ART, a further treatment approach is indicated. This protocol addresses that clinical situation.
Prior Treatment & Escalation Trigger
The preceding line involved initiation of antiretroviral therapy (ART) in ART-naive patients, or optimisation of ART — by switching or intensifying regimens after resistance testing — in pretreated or viremic patients. The goal was sustained HIV viral load suppression below the limit of detection, with sufficient immune reconstitution for KS lesions to stabilise or heal. This protocol is indicated when those targets have not been achieved: KS persists, progresses, or recurs despite ART.
Next-Line Treatment Approach
Systemic chemotherapy, given in combination with continued antiretroviral therapy, is the cornerstone of this treatment line. Depending on patient-specific factors, an immunomodulatory approach may also be considered as an alternative in certain patients. The full regimen — including agent selection, sequencing, and all dosing details — is available in the complete protocol.
Treatment Goals
The primary aim is regression of Kaposi sarcoma lesions, assessed by reduction in lesion size, thickness, and coloration, together with resolution of associated oedema. Partial remission is the standard measure of treatment success.
References
DOI: 10.1111/ddg.14788
- For systemic therapy of KS, chemotherapy with pegylated liposomal doxorubicin should be the first choice.
- Pegylated liposomal doxorubicine at a dose of 20 mg/m2 body surface area i.v. every 2–3 weeks can achieve partial remissions in up to 60–80 % of treated patients.
- An alternative for doxorubicine is liposomal daunorubicine, which is probably somewhat less effective.
- Liposomal daunorubicine (DaunoXome®) is given at a dose of 40 mg/m2 KO i.v. every two weeks.
- If KS recurs despite efficient ART or if existing KS does not show regression, low doses of IFN-α are usually sufficient to treat KS.
- Initially, in combination with ART, 3–9 million IU IFN-α are applied daily, later 3–5 x/week, s.c.
- Interferon should therefore only be considered in KS patients with more than 200 CD4 cells/μl.
- Treatment response is assessed by clinical examination of the lesions.
- In addition to subjective parameters, the size, thickness and coloration of the tumors as well as the presence of edema serve as criteria.
- In most cases, a profound partial remission is achieved after about 3–6 infusions, whereas some patients require more infusions to achieve a response.